Bayer AG (BAYGn.DE)

BAYGn.DE on Xetra

133.75EUR
11:35am EDT
Change (% chg)

€-1.25 (-0.93%)
Prev Close
€135.00
Open
€135.20
Day's High
€136.00
Day's Low
€131.95
Volume
1,909,916
Avg. Vol
2,391,754
52-wk High
€146.45
52-wk Low
€94.22

BAYGn.DE

Chart for BAYGn.DE

About

Bayer AG is a German holding company active in the field of health care, nutrition and high-tech materials. It has three subgroups: HealthCare, involved in the research, development and production of health products for people and animals, CropScience, engaged in the crop protection and non-agricultural pest control, and... (more)

Overall

Beta: 0.93
Market Cap(Mil.): €111,638.00
Shares Outstanding(Mil.): 826.95
Dividend: 2.25
Yield (%): 1.67

Financials

  BAYGn.DE Industry Sector
P/E (TTM): 33.77 36.70 40.26
EPS (TTM): 4.00 -- --
ROI: 6.84 16.44 15.71
ROE: 15.47 17.21 16.73
Search Stocks

Bayer says MaterialScience draws positive investor feedback

FRANKFURT, July 29 - Bayer's Chief Executive Marijn Dekkers told analysts in a conference call that the MaterialScience division's top management, which is preparing for a separate listing, has recently met with potential investors and received positive feedback.

29 Jul 2015

Bayer profit boosted by eye drug, better plastics margins

FRANKFURT - German drugmaker Bayer saw underlying core earnings increase by one third in the second quarter, helped by a gain in prescriptions of new drugs such as eye drug Eylea and lower raw material costs at its plastics division.

29 Jul 2015

UPDATE 2-Bayer profit boosted by eye drug, better plastics margins

* Plans to separately list MaterialScience unit on track (Adds share price, analyst comment, details on eye drug)

29 Jul 2015

European Factors to Watch-Shares seen opening higher

LONDON, July 29 - European stocks were seen opening higher on Wednesday, helped by a slight stabilisation in the hard-hit Chinese stock market while many investors were also expected to refrain from taking big positions before a policy decision from the U.S. Federal Reserve.

29 Jul 2015

BRIEF-Bayer and Sprint Bioscience collaborate in cancer research

* Bayer Healthcare enters into collaboration with Sprint Bioscience on tumor metabolism program

28 Jul 2015

European Factors to Watch-Shares seen higher, focus on earnings

LONDON, July 28 - European equities headed for a higher open on Tuesday after falling in the previous five sessions, with some strong company results and mergers and acquisitions news seen supporting the market.

28 Jul 2015

Glenmark Pharmaceuticals' Finacea generic infringes Bayer patent: court

NEW YORK - India's Glenmark Pharmaceuticals' proposed generic version of Bayer AG's Finacea, a gel for treating the common skin condition rosacea, infringes Bayer's patent, a U.S. court ruled on Monday.

27 Jul 2015

Glenmark Pharmaceuticals' Finacea generic infringes Bayer patent - court

NEW YORK, July 27 - India's Glenmark Pharmaceuticals' proposed generic version of Bayer AG's Finacea, a gel for treating the common skin condition rosacea, infringes Bayer's patent, a U.S. court ruled on Monday.

27 Jul 2015

Deals of the day- Mergers and acquisitions

July 17 - The following bids, mergers, acquisitions and disposals were reported by 2100 GMT on Friday:

17 Jul 2015

Bayer to talk to investors over summer on Covestro flotation: sources

FRANKFURT - German drugmaker Bayer plans to hold investor meetings over the summer as it prepares a stock market listing of its plastics division, sources familiar with the deal said.

17 Jul 2015

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: ValuEngine, Inc.
$49.00
Provider: ValuEngine, Inc.
$25.00
Provider: Finlabo SIM Spa
$10.00
Provider: Reuters Investment Profile
$20.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks